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Background-—Many patients with heart failure (HF) with reduced ejection fraction (HFrEF) experience improvement or recovery of
left ventricular ejection fraction (LVEF). Data on clinical characteristics, outcomes, and medical therapy in patients with HF with
improved ejection fraction (HFiEF) are scarce.
Methods and Results-—Of 5625 consecutive patients hospitalized for acute HF in the KorAHF (Registry [Prospective Cohort]
for Heart Failure in Korea) study, 5103 patients had baseline echocardiography and 2302 patients had follow-up
echocardiography at 12 months. HF phenotypes were deﬁned as persistent HFrEF (LVEF ≤40% at baseline and at 1-year
follow-up), HFiEF (LVEF ≤40% at baseline and improved up to 40% at 1-year follow-up), HF with midrange ejection fraction
(LVEF between 40% and <50%), and HF with preserved ejection fraction (LVEF ≥50%). The primary outcome was 4-year all-
cause mortality from the time of HFiEF diagnosis. Among 1509 HFrEF patients who had echocardiography 1 year after index
hospitalization, 720 (31.3%) were diagnosed as having HFiEF. Younger age, female sex, de novo HF, hypertension, atrial
ﬁbrillation, and b-blocker use were positive predictors and diabetes mellitus and ischemic heart disease were negative
predictors of HFiEF. During 4-year follow-up, patients with HFiEF showed lower mortality than those with persistent HFrEF in
univariate, multivariate, and propensity-score–matched analyses. b-Blockers, but not renin–angiotensin system inhibitors or
mineralocorticoid receptor antagonists, were associated with a reduced all-cause mortality risk (hazard ratio: 0.59; 95% CI,
0.40–0.87; P=0.007). Beneﬁts for outcome seemed similar among patients receiving low- or high-dose b-blockers (log-rank,
P=0.304).
Conclusions-—HFiEF is a distinct HF phenotype with better clinical outcomes than other phenotypes. The use of b-blockers may be
beneﬁcial for these patients.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT01389843. ( J Am Heart Assoc. 2019;8:
e011077. DOI: 10.1161/JAHA.118.011077.)
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H eart failure (HF) is currently classiﬁed as HF withreduced ejection fraction (HFrEF), HF with midrange
ejection fraction (HFmrEF), or HF with preserved ejection
fraction (HFpEF) based on left ventricular ejection fraction
(LVEF).1 Although the prognoses for the various HF
types appear to be similar, the level of neurohumoral activity
and the response to medical therapy differ among HF types,
suggesting differences in their underlying pathophysiology.2
Among patients with HFrEF, a subgroup experience the
restoration of LVEF with goal-directed medical therapy
(GDMT) and are classiﬁed as having HF with improved
ejection fraction (HFiEF).3–5 Data on demographics, etiology,
and prognosis remain scarce, especially in Asian patients
with HF.
Regarding treatment strategies, drugs targeting the
sympathetic nervous system and neurohumoral activation
have improved survival in patients with HFrEF6–9 but not in
those with HFpEF.10–13 It is unknown whether HFiEF would
behave like HFrEF or HFpEF in terms of response to
GDMT.
KorAHF (Registry [Prospective Cohort] for Heart Failure in
Korea) is a prospective, nationwide, multicenter cohort study
that consecutively enrolled patients with acute HF (AHF), and
every patient was scheduled to undergo echocardiography at
baseline and at 1 year after the index admission. Using this
registry, we sought to comprehensively investigate the clinical
characteristics, outcomes, and response to medical therapy of
patients with HFiEF.
Methods
The data that support the ﬁndings of this study are available
from the corresponding author on reasonable request.
Study Population and Data Collection
KorAHF was a prospective, multicenter cohort study, and the
design and preliminary results have been described elsewhere
(ClinicalTrial.gov identiﬁer NCT01389843).14,15 Brieﬂy, 5625
consecutive patients hospitalized for AHF in 10 tertiary univer-
sity hospitals in the Republic of Korea were enrolled between
March 2011 and December 2014. Patients who had signs or
symptoms of HF and lung congestion, objective ﬁndings of left
ventricular systolic dysfunction, or structural heart disease were
included in this study. There were no exclusion criteria.
Each patient was scheduled for follow-up at least 5 years
after the index hospitalization. The mortality data of patients
who were lost to follow-up were collected from National
Insurance data or National Death Records.
The institutional review board or ethics committee at each
participating hospital approved the study protocol and waived
the need for written informed consent. This study complied
with the Declaration of Helsinki principles.
Study Variables and Deﬁnitions
All echocardiographic studies were performed by cardiologists
who were certiﬁed by the Korean Society of Echocardiography,
using a standard ultrasound machine with a 2.5-MHz probe.
Standard techniques were adopted to obtain M-mode, 2-
dimensional, and Doppler measurements, in accordance with
the American Society of Echocardiography’s guidelines.16 LVEF
was measured using the Simpson biplane method, unless the
Simpson method was not possible. Based on the echocardiog-
raphy ﬁndings at the index AHF hospitalization, patients were
classiﬁed into those with HFrEF (LVEF ≤40%), HFmrEF (LVEF
between 40% and <50%), and HFpEF (LVEF ≥50%). All patients
were encouraged to undergo follow-up echocardiography at
1 year after the index hospitalization.AmongpatientswithHFrEF
at the index hospitalization, thosewhose LVEF improved to>40%
were considered to have HFiEF, whereas those with LVEF ≤40%
were considered to have persistent HFrEF (Figure 1A).
In terms of medication, the use of b-blockers for HF treatment
was deﬁned as a prescription for carvedilol, metoprolol, bisopro-
lol, or nebivolol, according to the recommendation of the current
guidelines.1,4 Use of renin–angiotensin system (RAS) inhibitors
was deﬁned as the administration of either an angiotensin-
converting enzyme inhibitor or an angiotensin II receptor blocker.
Theb-blocker name anddosewere evaluated in the year following
diagnosis of HFiEF. Low- and high-dose b-blockers were deﬁned
as thosewith1% to49%and≥50%of the target dose, respectively.
Clinical Perspective
What Is New?
• Among patients with heart failure with reduced ejection
fraction, left ventricular ejection fraction improves in a third.
Patients with heart failure with improved ejection fraction
(HFiEF) have better prognosis than other heart failure
phenotypes.
• Younger age, female sex, de novo onset, hypertension, atrial
ﬁbrillation, and b-blocker prescription are positive predic-
tors, whereas ischemic heart disease and diabetes mellitus
are negative independent predictors of HFiEF.
• The use of b-blockers, but not renin–angiotensin system
inhibitors or mineralocorticoid receptor antagonists, is asso-
ciated with reduced all-cause mortality among patients with
HFiEF.
What Are the Clinical Implications?
• HFiEF is a distinct heart failure phenotype with better
clinical outcomes than other phenotypes.
• b-Blockers should be continued in HFiEF patients.
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The target dose of the b-blockers was based on the clinical
guideline.1,17 Medication history at admission, during admission,
at discharge, and during follow-up (at 1, 3, 6, and 12months) was
recorded in the KorAHF registry.
The primary outcome was 4-year all-cause mortality from
time of HFiEF diagnosis.
Statistical Analysis
The data are presented as number and frequency for
categorical variables and as meanSD for continuous
variables. For comparison between groups, the v2 test (or
Fisher exact test when any expected cell count was <5 for a
292 table) was used for categorical variables and the
unpaired Student t test was used for continuous variables.
The chronological trends of the outcomes were expressed as
Kaplan–Meier estimates and compared by b-blocker use. The
log-rank test was performed for comparison of the differences
in the clinical outcomes. A multivariable Cox proportional
hazards regression model was used to determine the
independent predictors of all-cause mortality. Variables
associated with mortality with a P<0.05 were included as
confounding variables in the multivariate analysis. As a
sensitivity analysis, we performed both propensity-score–
A
B
Figure 1. Study population. A, Flowchart of the study. B, Patients demographics according to the ﬂowchart. EF indicates ejection fraction; HF,
heart failure; HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; KorAHF, Registry (Prospective Cohort) for Heart Failure in Korea.
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matched (PSM) and inverse-probability treatment-weighted
(IPTW) analysis. The propensity score was calculated using
multivariable logistic regression analysis, and the PSM
population was created using the nearest neighbor method
without replacement in a 1:1 ratio (the following variables
were included for matching: age, sex, body mass index,
previous history of heart failure, hypertension, diabetes
mellitus, ischemic heart disease, valvular heart disease,
chronic obstructive pulmonary disease, cerebrovascular dis-
ease, atrial ﬁbrillation, malignancy, New York Heart Associ-
ation functional class, and medication history of b-blockers,
renin–angiotensin system inhibitors, and mineralocorticoid
receptor antagonists). Considering reduction of participants
during PSM analysis, the IPTW analysis was also performed to
account for confounders. Success of PSM and IPTW analyses
was assessed by calculating standardized differences in the
baseline characteristics (Tables S1 and S2). We used the
“MatchIt” package for R programming for PSM analysis and
the “Twang” package for IPTW analysis.
A 2-sided P<0.05 was considered statistically signiﬁcant.
The statistical tests were performed using IBM SPSS v23 (IBM
Corp) and R v3.1.0 (R Foundation for Statistical Computing).
Results
Demographic and Clinical Characteristics
Among 5625 patients included in the KorAHF registry, 5103
patients underwent baseline echocardiographic evaluation.
Based on LVEF, 3088 (61%) patients were classiﬁed as having
HFrEF, 730 (14%) as having HFmrEF, and 1285 (25%) as having
HFpEF. During the following year, 889 had died and 1651 were
either lost to follow-up or did not undergo 1-year follow-up
echocardiography; therefore, the data of 2302 patients were
available for this analysis. Of these patients, 789 (34%) were
ﬁnally diagnosed with persistent HFrEF, 720 (31%) with HFiEF,
322 (14%) with HFmrEF, and 471 (20%) with HFpEF (Figure 1B).
Tables 1 and 2 present clinical characteristics of patients
with HFrEF at the index admission and at 1 year after index
admission. In brief, patients with HFiEF had more favorable
baseline characteristics: they were younger, showed a
preponderance of de novo HF, and had less hypertension,
diabetes mellitus, ischemic heart disease, and chronic
obstructive lung disease. Change of LVEF from index admis-
sion to 1-year follow-up was 13.715.1% in all, 2.77.6% in
persistent HFrEF, and 25.711.6% in HFiEF. The clinical
information of other HF phenotypes is presented in Table S3.
Predictors of HFiEF
The etiology and aggravating factors for AHF by HF phenotype
are presented in Figure 2A and 2C. Compared with patients
with persistent HFrEF, patients with HFiEF had less ischemic
but more tachycardia-induced cardiomyopathy.
We investigated independent predictors of HFiEF in patients
who were initially diagnosed as having HFrEF at baseline
(Table 3). In the multivariable analysis, younger age, female
sex, de novo HF, hypertension, atrial ﬁbrillation, and use of
b-blockers were positive independent predictors. In contrast,
diabetes mellitus, ischemic heart disease, and mineralocor-
ticoid receptor antagonist (MRA) prescription at discharge
were inversely associated with an HFiEF diagnosis.
Clinical Outcomes
The treatment and outcomes during the index hospitalization
are displayed in Table S4.
During 4-year follow-up, 116 (16%) patients with HFiEF
died, all of whom had more unfavorable characteristics, as
expected (Table S5). Patients with HFiEF showed better
prognosis (log-rank, P<0.001) than those with persistent
HFrEF in crude, PSM, and IPTW cohorts (Figure 3, Tables S1
and S2). Clinical outcomes of other HF phenotypes are
presented in Figure S1. Brieﬂy, those with HFiEF had the
lowest mortality (116 deaths, 16.1%) compared with those
with persistent HFrEF (270 deaths, 34.2%), HFmrEF (214
deaths, 33.5%), and HFpEF (149 deaths, 31.6%).
GDMT in HFiEF
Regarding the effect of GDMT in HFiEF, patients with b-
blockers had lower 4-year all-cause mortality in crude, PSM
and IPTW populations (Figure 4, Table S6, Figure S2).
In multivariate analysis, only the use of b-blockers was
associated with a 41% reduced risk of mortality (hazard ratio:
0.59; 95% CI, 0.40–0.87; P=0.007), whereas the effect of RAS
inhibitor and MRA use on mortality appeared to be neutral
(Table 4).
Effect of the Dose and Timing of Initiation of
b-Blockers
Among patients with HFiEF who took b-blockers, most received
carvedilol (216 patients, 48.8%) or bisoprolol (201 patients,
45.4%) whereas nebivolol (24 patients, 5.4%) and metoprolol (2
patients, 0.5%) were rarely used. There was no difference
between carvedilol and bisoprolol; however, because of the
small number of patients taking metoprolol and nebivolol, a
deﬁnite conclusion could not be drawn. Stratiﬁed by b-blocker
dose, patients who received either high- or low-dose b-blockers
at the time of diagnosis of HFiEF showed better 4-year mortality
than those who did not; however, there was no difference
between the patients who received low- and high-dose b-
blockers (log-rank, P=0.304; Figure S3).
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Table 1. Clinical Characteristics According to HF Phenotypes at the Index Admission
All HFrEF (n=1509) Persistent HFrEF (n=789) HFiEF (n=720) P Value
Demographic data
Age, y 62.415.2 65.014.1 59.515.8 <0.001
Men 937 (62.1) 516 (65.4) 421 (58.5) <0.001
BMI, kg/m2 23.73.8 23.63.5 23.74.1 0.507
De novo HF 833 (55.2) 354 (44.9) 479 (66.5) <0.001
Past medical history
Hypertension 757 (50.2) 409 (51.8) 348 (48.3) <0.001
Diabetes mellitus 495 (32.8) 319 (40.4) 176 (24.4) <0.001
Ischemic heart disease 378 (25.0) 267 (33.9) 111 (15.4) <0.001
Valvular heart disease 131 (8.7) 60 (7.6) 71 (9.9) 0.120
COPD 127 (8.4) 72 (9.1) 55 (7.6) 0.008
Cerebrovascular disease 167 (11.1) 100 (12.7) 67 (9.3) 0.037
Atrial fibrillation 326 (21.6) 163 (20.7) 163 (22.6) <0.001
Malignancy 123 (8.2) 55 (7.0) 68 (9.4) 0.079
Current smoking 341 (22.6) 176 (22.3) 165 (22.9) 0.777
NYHA functional class
II 240 (15.9) 124 (15.7) 116 (16.1) 0.532
III 595 (39.4) 302 (38.3) 293 (40.7)
IV 674 (44.7) 363 (46.0) 311 (43.2)
Physical examination
SBP, mm Hg 127.728.2 125.425.7 130.330.5 0.001
DBP, mm Hg 80.118.8 77.616.4 82.820.7 <0.001
HR, beats/min 94.724.7 92.523.5 97.125.7 <0.001
Laboratory examination
Hemoglobin, mg/dL 13.12.3 13.02.2 13.22.3 0.032
Sodium, mmol/L 137.94.5 137.94.4 137.94.5 0.772
Potassium, mmol/L 4.40.6 4.40.6 4.30.6 0.021
BUN, mg/dL 24.514.8 25.615.2 23.214.2 0.002
Creatinine, mg/dL 1.41.4 1.41.3 1.41.5 0.692
BNP, pg/mL 980.5 (533.3–1856.5) 927.0 (508.5–1685.0) 1063.0 (545.0–2078.0) 0.090
NT-proBNP, pg/mL 4688.0 (2363.5–10 491.2) 4785.0 (2419.0–11 784.0) 4453.0 (2336.0–9531.5) 0.221
Troponin I, ng/mL 0.06 (0.04–0.20) 0.06 (0.04–0.18) 0.06 (0.03–0.24) 0.198
Echocardiography
LAD, mm 47.79.0 48.38.7 47.09.3 0.004
LVEDD, mm 62.39.1 64.59.0 60.08.7 <0.001
LVESD, mm 53.09.9 55.39.8 50.59.5 <0.001
E/e0 21.811.1 22.811.7 20.610.3 0.001
RVSP, mm Hg 43.414.3 44.114.8 42.513.6 0.083
LVEF, % 26.27.4 25.37.1 27.37.6 <0.001
Medication
Β-Blocker 906 (60.0) 453 (57.4) 453 (62.9) 0.029
RASi 1186 (78.6) 622 (78.8) 564 (78.3) 0.813
MRA 840 (55.7) 472 (59.8) 368 (51.1) 0.001
Data are shown as n (%), meanSD, or median (interquartile range). BMI indicates body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive
pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate;
LAD, left atrial diameter; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MRA, mineralocorticoid
receptor antagonist; NT-proBNP, N-terminal proB-type natriuretic peptide; NYHA, New York Heart Association; RASi, renin-angiotensin system inhibitor; RVSP, right ventricular systolic
pressure; SBP, systolic blood pressure.
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Because the status of b-blocker prescription changed
between discharge from the index hospitalization and the time
of HFiEF diagnosis, we further categorized the patients into 4
groups according to b-blocker use at discharge and at HFiEF
diagnosis. In the Kaplan–Meier analysis, patients who were on
b-blockers at the time of HFiEF diagnosis had similar
prognoses, regardless of b-blocker use at discharge from
the index hospitalization (log-rank, P=0.497; Figure S3).
Subgroup Analysis
We performed exploratory subgroup analyses that included
age, sex, ischemic versus nonischemic etiology, HF onset (de
novo versus acute decompensated HF [ADHF]), chronic kidney
disease, diabetes mellitus, RAS inhibitor use, MRA use, and
changes in LVEF. There was no signiﬁcant interaction between
the b-blocker effect and subgroups, and b-blocker use was
consistently associated with reduced risk for 4-year all-cause
mortality across all subgroups (Figure S4).
Next, we stratiﬁed the patients by rhythm. Patients with a
b-blocker had better survival than patients without among
those with sinus rhythm but not among those with atrial
ﬁbrillation (Figure S5).
Regarding the onset of HF, 55% of the patients had de
novo HF and 45% had ADHF. Patients with HFiEF had better
survival than those with persistent HFrEF among both de
novo HF and ADHF patients (Figure S6). Regarding GDMT, b-
blocker use was associated with improved survival of both de
novo HF and ADHF patients. In Kaplan–Meier analysis, b-
blockers showed a therapeutic implication for de novo HF
(log-rank, P=0.016) but attenuated improvement in ADHF
(log-rank, P=0.089). After adjusting for covariates, both de
novo HFiEF (hazard ratio: 0.73; 95% CI, 0.54–1.00; P=0.049)
and acute decompensated HFiEF (hazard ratio: 0.57; 95% CI,
0.33–0.98, P=0.041) showed a beneﬁt of b-blockers. In
contrast, the effect of RAS inhibitors and MRAs appeared to
be neutral in both de novo HF and ADHF patients (Figures S7
and S8).
Table 2. Clinical Characteristics According to HF Phenotypes 1 Year After Index Admission (ie, at HFiEF diagnosis)
All HFrEF Persistent HFrEF (n=789) HFiEF (n=720) P Value
Physical examination
SBP, mm Hg 118.218.7 114.717.9 121.818.9 <0.001
DBP, mm Hg 70.612.7 68.412.0 72.812.9 <0.001
HR, bpm 78.215.6 78.416.1 78.115.2 0.767
Laboratory examination
Hemoglobin, mg/dL 12.72.1 12.82.1 12.72.0 0.371
Sodium, mmol/L 139.13.3 138.83.2 139.43.5 0.006
Potassium, mmol/L 4.50.5 4.50.5 4.50.5 0.072
BUN, mg/dL 24.514.5 25.915.2 22.813.5 0.001
Creatinine, mg/dL 1.51.6 1.61.5 1.51.6 0.423
Echocardiography
LAD, mm 44.48.8 46.98.4 41.68.4 <0.001
LVEDD, mm 57.710.0 63.68.8 51.26.7 <0.001
LVESD, mm 44.812.3 53.69.6 35.67.0 <0.001
E/e0 16.710.2 19.811.4 13.57.5 <0.001
RVSP, mm Hg 36.831.6 40.324.2 32.338.6 <0.001
LVEF, % 39.914.8 28.07.4 53.08.4 <0.001
DLVEF from index admission, % 13.715.1 2.77.6 25.711.6 <0.001
Medications
Β-Blocker 878 (63.3) 443 (60.9) 443 (65.8) 0.058
RASi 981 (70.7) 535 (74.9) 446 (66.3) <0.001
MRA 612 (44.1) 373 (52.2) 239 (35.5) <0.001
Data are shown as n (%) or meanSD. BUN indicates blood urea nitrogen; DBP, diastolic blood pressure; E/e0 , the ratio between early mitral inﬂow velocity and mitral annular early
diastolic velocity; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; LAD, left atrial diameter; LVEDD,
left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; MRA, mineralocorticoid receptor antagonist; RAS, renin-
angiotensin system inhibitor; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure.
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Discussion
In this comprehensive analysis of HFiEF, we investigated the
clinical characteristics, predictors, and prognostic outcomes
of patients with HFiEF in comparison with persistent HFrEF.
Younger age, de novo onset, and b-blocker prescription were
positive predictors; in contrast, ischemic heart disease and
diabetes mellitus were negative independent predictors of
HFiEF among patients with HFrEF at index admission.
Compared with persistent HFrEF, patients with HFiEF had
better prognosis, and the use of b-blockers was associated
with improved survival in these patients.
A
B C
Figure 2. Etiology and aggravating factors according to HF phenotypes. A, Proportion of HF etiology. B, Top 5 etiologic causes according to
the HF phenotypes. C, Five most common aggravating factors of acute HF according to the HF phenotypes. HF indicates heart failure; HFiEF,
heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
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Clinical Characteristics and Predictors of HFiEF
Understanding the clinical characteristics and predictors of
HFiEF provides important information and can be used for
risk stratiﬁcation and guidance of therapy in patients with
HF. In this study, we showed that younger age and de novo
HF were independent predictors of HFiEF. Previous studies
also found patients with LVEF improvement to be younger.18
Conversely, ischemic heart disease was a strong negative
predictor, in accordance with a report indicating that
patients with HFiEF had less coronary artery disease.6
Patients with ischemic cardiomyopathy have been found to
have less viable myocardium and more scarring; in addition,
owing to its irreversible nature, the extent of the myocardial
scar was found to correlate inversely with LVEF improve-
ment.19,20
Prognosis of Patients With HFiEF
The principal ﬁnding of this study pertains to mortality, and
patients with HFiEF had better prognosis compared not only
with HFpEF but also with other HF phenotypes (Figure 3,
Figure S1), with a remarkably reduced risk of 4-year all-cause
mortality. Our ﬁndings are consistent with previous studies
reporting the superior long-term clinical prognosis of patients
with HFiEF compared with the other HF phenotypes.3,5
Notably, patients with HFiEF required more catecholamines
and mechanical circulatory support device assistance during
the index admission, indicating a more serious in-hospital
course in contrast to the ultimately favorable long-term
outcomes. This implies that in patients with HFrEF who survive
the ﬁrst year, the more serious in-hospital course does not
necessarily equate to grave long-termpostdischarge outcomes.
GDMT in HFiEF
Another principal ﬁnding was related to the effect of GDMT
in patients with HFiEF. We found that the use of b-blockers,
Table 3. Independent Predictors of HFiEF Among Patients
With HFrEF at the Index Admission
OR 95% CI P Value
Age 0.98 0.97–0.99 <0.001
Male 0.65 0.52–0.81 <0.001
De novo onset 2.23 1.77–2.80 <0.001
Hypertension 1.31 1.05–1.65 0.020
Diabetes mellitus 0.55 0.43–0.70 <0.001
Ischemic heart disease 0.58 0.45–0.76 <0.001
Atrial fibrillation 1.77 1.36–2.32 <0.001
Β-Blocker at discharge 1.28 1.03–1.59 0.024
MRA at discharge 0.59 0.47–0.73 <0.001
ORs have been adjusted for age, sex, de novo heart failure, previous history of
hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary
disease, cerebrovascular accident, atrial ﬁbrillation and malignancy, New York Heart
Association functional class, b-blocker at discharge, renin–angiotensin system inhibitor
at discharge, and MRA at discharge. HFiEF indicates heart failure with improved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid
receptor antagonist; OR, odds ratio.
A B C
Figure 3. Clinical outcomes according to HFiEF and persistent HFrEF. A, Kaplan–Meier survival curves for 4-year mortality according to HF
phenotypes. As sensitivity analyses, the PSM cohort (B) and the IPTW cohort (C) were also analyzed. The curves are left-truncated at 4 years
after index admission. HFiEF, heart failure with improved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IPTW, inverse-
probability treatment weighted; PSM, propensity score matching.
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but not the use of RAS inhibitors or MRAs, was associated
with improved survival. This ﬁnding is crucial and has
important clinical implications: In patients with HFrEF, b-
blockers should be continued even after the restoration of
LVEF. Interestingly, there was no difference in mortality
between the patients with high- and low-dose b-blockers in
our study. Considering the similar prognoses for those
taking low- or high-dose b-blockers, careful dose reduction
of b-blockers may be possible for patients with HFiEF who
do not tolerate b-blockers well. Furthermore, we showed
that b-blocker use at HFiEF diagnosis was associated with
improved survival regardless of the prescription of b-
blockers at hospital discharge. This ﬁnding suggests that
all patients with HFiEF could beneﬁt from b-blocker use. The
reasons for the lack of effect of RAS inhibitors and MRAs
are not clear.
Strengths and Limitations
This study has several limitations. First, because this study is a
post hoc analysis of a prospective cohort study, albeit a large
one, as opposed to a randomized controlled trial, there could be
unmeasured confounding factors. Second, we enrolled only
patients who underwent echocardiographic assessment at
A
B
Figure 4. Impact of GDMT on 4-year mortality in HFiEF patients (A) and persistent HFpEF patients (B). GDMT indicates goal-directed medical
therapy; HFrEF, heart failure with reduced ejection fraction; HFiEF, heart failure with improved ejection fraction; MRA, mineralocorticoid receptor
antagonists; RASi, renin–angiotensin system inhibitor.
DOI: 10.1161/JAHA.118.011077 Journal of the American Heart Association 9
Characteristics of HFiEF Park et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on May 19, 2019
1 year after index admission, and this approach may have led
to selection and lead-time biases, possibly favoring less ill
patients or those with better compliance, in this substudy
(Table S7). Third, because the participants comprise only East
Asian patients, it is unknown whether the results can be
extrapolated to other ethnicities and countries. In addition, we
assessed left ventricular systolic function by LVEF, but even
patients with “normal” LVEF might have impaired left ventric-
ular systolic function.21 In addition, b-blocker, RAS inhibitor,
and MRA administration may have been altered, and other
factors could be related to medication during the follow-up
period. Although we evaluated the therapeutic implications of
GDMT including b-blockers, RAS inhibitors, and MRAs, further
studies are necessary to validate the prognostic value of
sacubitril or valsartan in patients with HFiEF. Digoxin and loop
diuretics have been prevalently prescribed to manage patients
with AHF, but these patients did not show signiﬁcant prognos-
tic improvement (Figure S9). In addition, we deﬁned de novo HF
based on medical history of HF.22–24 Last, we did not perform
core laboratory analysis of the echocardiographic measure-
ment of LVEF.
This study also has speciﬁc strengths. The KorAHF registry
is a well-designed, nationwide, prospective cohort study in
which every patient was scheduled to undergo echocardiogra-
phy at baseline and 1 year after index admission and to be
followed up for at least 5 years after index hospitalization. This
design facilitates a deﬁnitive diagnosis of HFiEF, the identiﬁ-
cation of predictors, and the demonstration of its natural
history; thanks to the prospective design and follow-up
schedule, the KorAHF registry could identify more patients
with HFiEF than previously reported.3,5,25 Furthermore, we
were also able to investigate the effect of GDMT in patients with
HFiEF for the ﬁrst time. Considering that LVEF improvement by
GDMT was often observed between 6 and 12 months after the
initiation of therapy,26,27 echocardiographic assessment of
LVEF at 1 year may be the appropriate timing for the detection
of HFiEF. To minimize bias by indication, we performed several
sensitivity analyses, and the protective relationship between b-
blocker use and clinical outcomes was consistent in the
univariate, multivariate, PSM and IPTW analyses. Despite the
strengths of this study, a randomized clinical trial is necessary
to rigorously evaluate the effect of GDMT in patients with
HFiEF.
Conclusions
HFiEF is a unique disease entity that has superior clinical
outcomes. Younger age, de novo HF, nonischemic heart
disease, and a b-blocker prescription are independent
predictors of HFiEF.
Table 4. Cox Regression Analysis for 4-Year Mortality From HFiEF Diagnosis
Unadjusted Adjusted
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Age 1.06 1.04–1.07 <0.001 1.05 1.03–1.06 <0.001
Male 1.28 0.88–1.87 0.198
De novo onset 0.41 0.28–0.59 <0.001 0.53 0.35–0.79 0.002
Hypertension 1.99 1.36–2.90 <0.001 0.96 0.60–1.52 0.852
Diabetes mellitus 2.41 1.67–3.48 <0.001 1.39 0.90–2.16 0.140
Ischemic heart disease 2.93 1.98–4.33 <0.001 1.56 0.99–2.46 0.055
COPD 1.01 0.51–2.00 0.971
Cerebrovascular disease 3.21 2.07–4.96 <0.001 2.09 1.29–3.38 0.003
Atrial fibrillation 0.78 0.52–1.18 0.234
Malignancy 1.52 0.88–2.62 0.130
NYHA functional class
II 1 Reference 0.079
III 1.22 0.67–2.24
IV 1.74 0.97–3.10
Β-Blocker at HFiEF diagnosis 0.54 0.37–0.80 0.002 0.59 0.40–0.87 0.007
RASi at HFiEF diagnosis 0.69 0.46–1.02 0.063
MRA at HFiEF diagnosis 1.12 0.75–1.67 0.570
Adjusted hazard ratios were adjusted for variables that showed P<0.05 in univariate analysis. COPD indicates chronic obstructive pulmonary disease; HFiEF, heart failure with improved
ejection fraction; MRA, mineralocorticoid antagonist; NYHA, New York Heart Association; RASi, renin–angiotensin system inhibitor.
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Characteristics of matched population 
Table S1. Clinical characteristics in propensity score-matched population 
N=1344 
HFiEF 
(n=672) 
Persistent 
HFrEF 
(n=672) 
Absolute 
mean 
difference 
p-value 
Demographic data     
Age (years) 59.6±15.7 65.3±13.7 4.844 <0.001 
Men (%) 400 (59.5) 448 (66.7) 0.060 0.008 
Body mass index (kg/m2) 23.8±4.2 23.5±3.5 0.141 0.252 
De novo heart failure (%) 441 (65.6) 291 (43.3) 0.176 <0.001 
Past Medical History     
Hypertension 327 (48.7) 333 (49.6) 0.025 0.743 
Diabetes mellitus 165 (24.6) 286 (42.6) 0.152 <0.001 
Ischemic Heart Disease 105 (15.6) 237 (35.3) 0.150 <0.001 
Valvular Heart Disease 70 (10.4) 49 (7.3) 0.022 0.044 
COPD 54 (8.0) 63 (9.4) 0.012 0.384 
Cerebrovascular disease 59 (8.8) 87 (12.9) 0.033 0.014 
Atrial fibrillation 155 (23.1) 131 (19.5)  0.021 0.110 
Malignancy 67 (10.0) 42 (6.3) 0.030 0.012 
Current Smoking 159 (23.7) 146 (21.7) 0.010 0.397 
NYHA functional class (%)   0.042 0.528 
II 111 (16.5) 102 (15.2)   
III 273 (40.6) 262 (39.0)   
IV 288 (42.9) 308 (45.8)   
Beta-blocker (%)     
at discharge 422 (62.8) 385 (57.3) 0.034 0.039 
at HFiEF diagnosis 442 (65.8) 400 (59.5) 0.027 0.018 
RAS-inhibitor (%)     
at discharge 529 (78.7) 522 (77.7) 0.153 0.644 
at HFiEF diagnosis 445 (66.2) 510 (75.9) 0.006 <0.001 
MRA (%)     
at discharge  348 (51.8) 411 (61.2) 0.042 0.001 
at HFiEF diagnosis 238 (35.4) 367 (54.6) 0.073 <0.001 
COPD, chronic obstructive pulmonary disease; HFiEF, heart failure with improved ejection fraction; MRA, 
Mineralocorticoid receptor antagonist; NYHA, New York Heart Association; RAS-inhibitor, renin-angiotensin-system 
inhibitor  
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Table S2. Clinical characteristics in inverse probability treatment weight-adjusted population 
N=2,676 
HFiEF 
(n=1327) 
Persistent 
HFrEF 
(n=1349) 
Absolute 
mean 
difference 
p-value 
Demographic data     
Age (years) 61.9±15.2 63.2±14.7 0.089 0.112 
Men (%) 818 (61.6) 864 (64.1) 0.051 0.360 
Body mass index (kg/m2) 23.7±3.8 23.6±3.6 0.022 0.690 
De novo heart failure (%) 787 (59.3) 721 (53.5) 0.118 0.038 
Past Medical History     
Hypertension 684 (51.5) 688 (51.0) 0.010 0.859 
Diabetes mellitus 415 (31.3) 477 (35.4) 0.087 0.123 
Ischemic Heart Disease 310 (23.4) 362 (26.9) 0.083 0.157 
Valvular Heart Disease 120 (9.1) 106 (7.9) 0.043 0.436 
COPD 110 (8.3) 113 (8.4) 0.003 0.951 
Cerebrovascular disease 139 (10.4) 158 (11.7) 0.040 0.476 
Atrial fibrillation 298 (22.5) 282 (20.9) 0.039 0.958 
Malignancy 117 (8.8) 101 (7.5) 0.048 0.391 
Current Smoking 302 (22.7) 305 (22.6) 0.003 0.478 
NYHA functional class (%)   0.005 0.958 
II 205 (15.5) 219 (16.2)   
III 529 (39.9) 512 (38.0)   
IV 593 (44.7) 618 (45.8)   
Beta-blocker (%)     
at discharge 826 (62.3) 802 (59.5) 0.057 0.305 
at HFiEF diagnosis 813 (66.1) 786 (63.6) 0.052 0.370 
RAS-inhibitor     
at discharge 1048 (79.0) 1055 (78.2) 0.018 0.157 
at HFiEF diagnosis 865 (70.3) 913 (73.4) 0.082 0.490 
MRA     
at discharge 726 (54.7) 777 (57.6) 0.076 0.300 
at HFiEF diagnosis 522 (42.4) 571 (46.1) 0.038 0.194 
* Abbreviations as in Supplemental Table 1  
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Patients with HFrEF, HFmrEF, and HFpEF 
In this study 2,302 patients in the KorAHF registry had echocardiography both at baseline and 1 year after index admission. The patients were 
stratified according to HF types.  
 
Table S3. Clinical characteristics according to HF phenotypes at the index admission 
 
Persistent HFrEF 
(n=789) 
HFiEF 
(n=720) 
HFmrEF 
(n=322) 
HFpEF 
(n=471) 
p-value 
Demographic data      
Age (years) 65.0±14.1 59.5±15.8 67.7±14.2 69.3±13.9 <0.001 
Men (%) 516 (65.4) 421 (58.5) 152 (47.2) 189 (40.1) <0.001 
BMI (kg/m2) 23.6±3.5 23.7±4.1 23.8±3.8 24.2±4.1 0.045 
De novo HF (%) 354 (44.9) 479 (66.5) 187 (58.1) 242 (51.4) <0.001 
Past Medical History (%)      
Hypertension 409 (51.8) 348 (48.3) 195 (60.6) 287 (60.9) <0.001 
Diabetes mellitus 319 (40.4) 176 (24.4) 111 (34.5) 144 (30.6) <0.001 
Ischemic heart disease 267 (33.9) 111 (15.4) 87 (27.0) 107 (22.7) <0.001 
Valvular heart disease 60 (7.6) 71 (9.9) 54 (16.8) 152 (32.3) <0.001 
COPD 72 (9.1) 55 (7.6) 36 (11.2) 63 (13.4) 0.008 
Cerebrovascular disease 100 (12.7) 67 (9.3) 46 (14.3) 59 (12.5) 0.071 
Atrial fibrillation 163 (20.7) 163 (22.6) 89 (27.6) 181 (38.5) <0.001 
Malignancy 55 (7.0) 68 (9.4) 28 (8.7) 27 (5.7) 0.084 
Current Smoking 176 (22.3) 165 (22.9) 45 (14.0) 54 (11.5) <0.001 
NYHA functional class (%)     0.382 
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II 124 (15.7) 116 (16.1) 52 (16.1) 92 (19.5)  
III 302 (38.3) 293 (40.7) 128 (39.8) 192 (40.8)  
IV 363 (46.0) 311 (43.2) 142 (44.1) 187 (39.7)  
Physical exam at index admission      
SBP (mmHg) 125.4±25.7 130.3±30.5 137.3±31.7 134.3±29.3 <0.001 
DBP (mmHg) 77.6±16.4 82.8±20.7 79.2±20.3 76.4±18.3 <0.001 
HR (beats per min) 92.5±23.5 97.1±25.7 89.1±22.8 84.3±24.4 <0.001 
Laboratory exam at index 
admission 
     
Hemoglobin (mg/dL) 13.0±2.2 13.2±2.3 12.2±2.4 12.1±2.1 <0.001 
Sodium (mmol/L) 137.9±4.4 137.9±4.5 138.2±4.3 137.9±4.7 0.670 
Potassium (mmol/L) 4.4±0.6 4.3±0.6 4.4±0.6 4.3±0.7 0.020 
BUN (mg/dL) 25.6±15.2 23.2±14.2 24.0±13.3 23.1±13.1 0.004 
Creatinine (mg/dL) 1.4±1.3 1.4±1.5 1.4±1.3 1.2±1.0 0.042 
BNP (pg/mL) 
927.0 
(508.5-1685.0) 
1063.0  
(545.0-2078.0) 
763.5 
(410.3-1403.5) 
529.0 
(203.5-904.8) 
<0.001 
NT-proBNP (pg/mL) 
4785.0 
(2419.0-11784.0) 
4453.0 
(2336.0-9531.5) 
4356.0 
(1960.0-11457.0) 
2438.5 
(1059.8-4204.0) 
<0.001 
Troponin I (ng/mL) 
0.06 
(0.04-0.18) 
0.06 
(0.03-0.24) 
0.10 
(0.04-0.73) 
0.04 
(0.02-0.09) 
<0.001 
Echocardiography at index 
admission 
     
LAD (mm) 48.3±8.7 47.0±9.3 47.9±9.9 50.3±11.9 <0.001 
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LVEDD (mm) 64.5±9.0 60.0±8.7 54.6±7.3 50.4±7.5 <0.001 
LVESD (mm) 55.3±9.8 50.5±9.5 40.8±6.8 32.7±6.1 <0.001 
E/e’ 22.8±11.7 20.6±10.3 19.7±10.8 20.2±12.1 <0.001 
RVSP (mmHg) 44.1±14.8 42.5±13.6 41.2±13.9 44.6±16.9 0.020 
LVEF (%) 25.3±7.1 27.3±7.6 44.3±2.9 59.2±6.2 <0.001 
Medication (%)      
Beta-blocker 453 (57.4) 453 (62.9) 181 (56.2) 153 (32.5) <0.001 
RAS-inhibitor 622 (78.8) 564 (78.3) 223 (69.3) 246 (52.2) <0.001 
MRA 472 (59.8) 368 (51.1) 128 (39.8) 192 (40.8) <0.001 
BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; DBP, diastolic 
blood pressure; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; 
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; LAD, left atrial diameter; 
LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic diameter; MRA, 
mineralocorticoid receptor antagonist; NT-proBNP, N-terminal proB-type natriuretic peptide; NYHA, New York Heart Association; RAS, renin-
angiotensin system; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure 
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Figure S1 Clinical outcomes according to HF phenotypes 
 
HFiEF, heart failure with improved ejection fraction; HFmrEF, heart failure with midrange 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure 
with reduced ejection fraction 
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HFrEF: HFiEF versus persistent HFrEF 
Table S4. In-hospital treatment during index hospitalization according to HF phenotypes 
 
Persistent HFrEF 
(n=789) 
HFiEF 
(n=720) 
p-value 
Total hospital (day) 12.2±10.5 16.2±19.4 <0.001 
ICU admission (%) 365 (46.3) 387 (53.8) 0.004 
ICU duration (days) 2.0±4.6 2.9±6.8 0.006 
Pharmacological treatments    
Parenteral medication (%)    
Nitroglycerin  283 (35.9) 289 (40.1) 0.088 
Nitroprusside  4 (0.5) 18 (2.5) 0.001 
Norepinephrine  49 (6.2) 64 (8.9) 0.048 
Milrinone  14 (1.8) 29 (4.0) 0.009 
Dopamine  110 (13.9) 142 (19.7) 0.003 
Dobutamine  219 (27.8) 189 (26.3) 0.510 
Diuretics  589 (74.7) 522 (72.5) 0.343 
Oral medication (%)    
Nitrates  431 (54.6) 399 (55.4) 0.758 
Hydralazine  12 (1.5) 26 (3.6) 0.010 
Loop diuretics  756 (95.8) 667 (92.6) 0.008 
Thiazide  110 (13.9) 105 (14.6) 0.722 
Amiodarone  125 (15.8) 131 (18.2) 0.224 
Digoxin  294 (37.3) 293 (40.7) 0.172 
Heparin/LWMH  332 (42.1) 359 (49.9) 0.002 
Warfarin  230 (29.2) 278 (38.6) <0.001 
Aspirin  567 (71.9) 410 (56.9) <0.001 
Non-pharmacological treatments 
(%) 
   
Blood transfusion  104 (13.2) 142 (19.7) 0.001 
Mechanical ventilation  84 (10.6) 112 (15.6) 0.005 
CRT  18 (2.3) 8 (1.1) 0.081 
ICD  23 (2.9) 9 (1.3) 0.025 
PCI  94 (11.9) 71 (9.9) 0.202 
CABG  30 (3.8) 21 (2.9) 0.342 
Valve operation  15 (1.9) 24 (3.3) 0.080 
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ECMO/PCPS  19 (2.4) 23 (3.2) 0.354 
CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; ECMO, 
extracorporeal membrane oxygenation; HFiEF, heart failure with improved ejection fraction; 
HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved 
ejection fraction; HFrEF, heart failure with reduced ejection fraction; IABP, intraaortic balloon 
pump; ICD, intracardiac defibrillator; ICU, intensive care unit; LMWH, low molecular heparin; 
PCI, percutaneous coronary intervention; PCPS, percutaneous cardiopulmonary support 
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Table S5. Clinical characteristics of patients with HFiEF according to 4-year all-cause mortality 
from HFiEF diagnosis 
 
Alive 
(n=604) 
Deceased 
(n=116) 
p-value 
Demographic data    
Age (years) 57.5±15.4 69.8±13.4 <0.001 
Men (%) 347 (57.5) 74 (63.8) 0.204 
BMI (kg/m2) 24.0±4.2 22.4±3.3 <0.001 
De novo HF (%) 424 (70.2) 55 (47.4) <0.001 
Past Medical History (%)    
Hypertension 274 (45.4) 74 (63.8) <0.001 
Diabetes mellitus 127 (21.0) 49 (42.2) <0.001 
Ischemic heart disease 74 (12.3) 37 (31.9) <0.001 
Valvular heart disease 63 (10.4) 8 (6.9) 0.242 
COPD 46 (7.6) 9 (7.8) 0.958 
Cerebrovascular disease 41 (6.8) 26 (22.4) <0.001 
Atrial fibrillation 132 (21.9) 31 (26.7) 0.251 
Malignancy 53 (8.8) 15 (12.9) 0.161 
Current Smoking 145 (24.0) 20 (17.2) 0.112 
NYHA functional class (%)   0.074 
II 102 (16.9) 14 (12.1)  
III 252 (41.7) 41 (35.3)  
IV 250 (41.4) 61 (52.6)  
Physical exam at index 
admission 
   
SBP (mmHg) 129.6±30.7 133.6±29.5 0.206 
DBP (mmHg) 83.0±21.0 81.7±18.8 0.531 
HR (beats per min) 97.5±26.2 95.0±23.3 0.301 
Physical exam at 1 year 
follow-up 
   
SBP (mmHg) 121.9±18.5 121.1±21.3 0.727 
DBP(mmHg) 73.4±12.9 68.9±11.9 0.003 
HR (beats per min) 77.5±14.9 81.3±16.7 0.055 
Laboratory exam at index 
admission 
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Hemoglobin (mg/dL) 13.4±2.3 12.4±2.2 <0.001 
Sodium (mmol/L) 137.9±4.5 137.8±4.8 0.958 
Potassium (mmol/L) 4.3±0.6 4.4±0.7 0.128 
BUN (mg/dL) 22.4±13.6 27.7±16.1 0.001 
Creatinine (mg/dL) 1.3±1.4 1.9±2.1 0.004 
BNP (pg/mL) 
1060.0 
(533.0-1918.0) 
1501.5 
(668.0-3090.5) 
0.084 
NT-proBNP (pg/mL) 
3982.0 
(2201.5-8133.5) 
7623.0 
(3247.0-15893.0) 
0.004 
Troponin I (ng/mL) 
0.05 
(0.03-0.23) 
0.08 
(0.04-0.29) 
0.136 
Laboratory exam at 1 year 
follow-up 
   
Hemoglobin (mg/dL) 12.8±2.1 12.1±1.9 0.011 
Sodium (mmol/L) 139.7±3.2 138.2±4.6 0.015 
Potassium (mmol/L) 4.5±0.5 4.4±0.7 0.360 
BUN (mg/dL) 22.0±12.8 26.9±16.1 0.018 
Creatinine (mg/dL) 1.4±1.5 1.9±2.1 0.075 
Echocardiography at index 
admission 
   
LAD (mm) 46.9±8.9 47.7±11.2 0.386 
LVEDD (mm) 60.3±8.8 58.5±8.5 0.045 
LVESD (mm) 51.0±9.5 48.0±9.2 0.002 
E/e’ 20.3±10.2 22.0±10.5 0.131 
RVSP (mmHg) 42.6±13.6 42.4±14.0 0.896 
LVEF (%) 26.8±7.5 29.9±7.2 <0.001 
Echocardiography at 1 year 
follow-up 
   
LAD (mm) 41.3±8.1 43.5±9.3 0.017 
LVEDD (mm) 51.1±6.5 51.7±7.8 0.408 
LVESD (mm) 35.3±6.9 37.0±7.6 0.020 
E/e’ 13.2±0.8 15.2±0.7 0.013 
RVSP (mmHg) 29.2±13.6 45.7±87.1 0.095 
LVEF (%) 53.7±8.3 49.5±8.1 <0.001 
Δ LVEF (%) 26.9±11.2 19.6±11.9 <0.001 
Beta-blocker (%)    
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at discharge 388 (64.2) 65 (56.0) 0.094 
at 1 year follow-up 389 (68.1) 54 (52.9) 0.003 
RAS-inhibitor (%)    
at discharge 481 (79.6) 83 (71.6) 0.053 
at 1year follow-up 386 (67.6) 60 (58.8) 0.084 
MRA (%)    
at discharge 307 (50.8) 61 (52.6) 0.729 
at 1year follow-up 200 (35.0) 39 (38.2) 0.533 
BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; COPD, 
chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; HFiEF, 
heart failure with improved ejection fraction; HFmrEF, heart failure with midrange ejection 
fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with 
reduced ejection fraction; HR, heart rate; LAD, left atrial diameter; LVEDD, left ventricular end 
diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic 
diameter; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal proB-type 
natriuretic peptide; NYHA, New York Heart Association; RAS, renin-angiotensin system; RVSP, 
right ventricular systolic pressure; SBP, systolic blood pressure;  
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Effect of beta-blockers in patients with HFiEF 
Because beta blockers appear to be effective in patients with HFiEF on long-term outcomes, 
we performed additional analyses. 
The baseline characteristics according to beta-blocker use are summarized in Table 
S6. In brief, the patients who received beta-blockers were more likely to be men and have a 
higher incidence of de-novo HF but a lower incidence of valvular heart disease and atrial 
fibrillation, at the time of diagnosis of HFiEF. There was no difference in the blood pressure 
between the groups; however, the heart rate was lower in the patients who received beta-
blockers. Regarding medical therapy, patients who received beta-blockers were administered 
renin-angiotensin system (RAS) inhibitors and mineralocorticoid antagonists (MRAs) more 
frequently also at the time of diagnosis of HFiEF. 
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Table S6. Baseline characteristics according to beta-blocker medication at the diagnosis of 
HFiEF 
 
Without 
Βeta-blocker 
(n=230) 
With 
Beta-blocker 
(n=443) 
p-value 
Demographic data    
Age (years) 59.6±16.8 59.6±15.1 0.985 
Men (%) 122 (53.0) 279 (63.0) 0.013 
Body mass index (kg/m2) 22.8±3.7 24.3±4.3 <0.001 
De novo heart failure (%) 132 (57.4%) 309 (69.8%) 0.001 
Past Medical History (%)    
Hypertension 104 (45.2) 104 (45.2) 0.207 
Diabetes mellitus 56 (24.3) 109 (24.6) 0.941 
Ischemic Heart Disease 39 (17.0) 66 (14.9) 0.485 
Valvular Heart Disease 34 (14.8) 36 (8.1) 0.007 
COPD 19 (8.3) 35 (7.9) 0.870 
Cerebrovascular disease 25 (10.9) 34 (7.7) 0.165 
Atrial fibrillation 66 (28.7) 89 (20.1) 0.012 
NYHA functional class (%)   0.755 
II 40 (18.4) 71 (16.0)  
III 96 (41.7) 178 (40.2)  
IV 94 (40.9) 194 (43.8)  
Physical exam at discharge    
Systolic blood pressure (mmHg) 112.7±17.9 114.7±16.7 0.153 
Diastolic blood pressure (mmHg) 67.8±11.4 69.4±11.8 0.085 
Heart rate (beats per min) 78.8±14.4 77.0±13.0 0.115 
Physical exam at HFiEF diagnosis    
Systolic blood pressure (mmHg) 120.4±18.4 122.5±19.1 0.204 
Diastolic blood pressure (mmHg) 72.5±12.0 72.9±13.3 0.721 
Heart rate (beats per min) 83.5±16.9 75.6±13.7 <0.001 
Echocardiography at index 
admission 
   
Left atrial diameter (mm) 47.2±10.7 47.1±8.3 0.894 
LVEDD (mm) 59.3±9.7 60.8±8.0 0.040 
LVESD (mm) 49.7±10.4 51.4±8.7 0.043 
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E/e’ 21.2±11.8 20.3±9.1 0.388 
LVEF (%) 28.2±7.5 26.7±7.5 0.015 
Echocardiography at HFiEF 
diagnosis 
   
Left atrial diameter (mm) 41.6±9.7 41.8±7.7 0.774 
LVEDD (mm) 49.6±7.0 52.1±6.4 <0.001 
LVESD (mm) 33.7±7.3 36.7±6.7 <0.001 
E/e’ 13.7±7.8 13.3±6.4 0.527 
LVEF (%) 54.7±8.9 52.1±8.0 <0.001 
Δ LVEF (%) 26.5±13.4 25.4±10.9 0.272 
Beta blocker (%)    
at discharge 59 (25.7) 364 (82.2) <0.001 
RAS-inhibitor (%)    
at discharge 155 (67.4) 375 (84.7) <0.001 
at HFiEF diagnosis 103 (44.8) 343 (77.4) <0.001 
MRA (%)    
at discharge 101 (43.9) 248 (56.0) 0.003 
at HFiEF diagnosis 49 (21.3) 190 (42.9) <0.001 
COPD, chronic obstructive pulmonary disease; HFiEF, heart failure with improved ejection 
fraction; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; 
LVESD, left ventricular end systolic diameter; MRA, Mineralocorticoid receptor antagonist; 
NYHA, New York Heart Association; RAS-inhibitor, renin-angiotensin system inhibitor 
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Propensity-score matching and inverse-probability treatment weighted analyses 
In crude population, patients with beta-blockers had better 4-year all-cause mortality from 
HFiEF diagnosis. To minimize the bias by indication, we performed propensity-score 
matching (PSM) and inverse-probability treatment weighted (IPTW) analyses as sensitivity 
analyses. A total of 460 patients were 1:1-matched based on their propensity score. The 
baseline characteristics of the cohort after matching were well balanced, except for 
medication. In both analyses, beta-blocker use was associated with reduced 4-year all-cause 
mortality from HFiEF diagnosis (Figure S2).  
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Figure S2 Beta-blockers in HFiEF after adjustment 
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Following variables were included for: age, sex, body mass index, previous history of heart failure, hypertension, diabetes 
mellitus, ischemic heart disease, valvular heart disease, chronic obstructive pulmonary disease, cerebrovascular disease, atrial 
fibrillation, malignancy, and New York Heart Association functional class. 
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Clinical outcomes according to beta-blocker dose and administration duration 
When the subjects were stratified according to the beta-blocker dose, patients who received 
either high- or low-dose beta-blockers at the time of diagnosis of HFiEF showed better 4-year 
mortality than those who did not (log-rank P=0.014 and log-rank P=0.004, respectively); 
however, there was no difference between the patients who received low- and high-dose beta-
blockers (log-rank P=0.846) (Figure S3). 
Because the status of beta-blocker prescription changed between discharge from the 
index hospitalization and the time of HFiEF diagnosis, we further categorized the patients 
into four groups according to beta-blocker use at discharge and at HFiEF diagnosis. In the 
Kaplan-Meier analysis, patients who were on beta-blockers at the time of HFiEF diagnosis 
had a similar prognosis, regardless of beta-blocker use or not at discharge from the index 
hospitalization (log-rank P=0.014).  
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Figure S3 Beta-blockers in HFiEF according to dose and duration 
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Subgroup analysis 
Figure S4 Association between the 4-year all-cause mortality and beta-blocker use in the subgroups of patients with HFiEF 
 
In the exploratory subgroup analysis, the effect of beta-blockers was consistent across all subgroups. 
The squares with horizontal lines indicate the HRs and corresponding 95% CIs.  
CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; HFiEF, heart failure with improved ejection fraction; HR, hazard ratio; IHD, 
ischemic heart disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; RASi, renin-angiotensin system inhibitor  
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Clinical outcomes according to rhythm: sinus rhythm versus atrial fibrillation 
We stratified the patients according to rhythm. In patients with sinus rhythm, patients with beta-blockers had better survival than those 
without beta-blockers. By contrast, in patients with atrial fibrillation there was no difference between those with and without beta-blockers 
(Figure S5). 
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Figure S5 Beta blockers in HFiEF according to rhythm 
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VI. Stratification according to onset of heart failure 
Regarding the onset of heart failure, 55% and 45% of the patients had de-novo and acutely-
decompensated heart failure (ADHF), respectively. Overall, patients with de-novo onset had 
better outcomes than those with ADHF. Patients with HFiEF had better survival than those 
with persistent HFrEF in both de-novo HF and ADHF (Figure S6). 
Regarding drug efficacy, patients with beta-blocker had lower mortality than those 
without beta-blocker in de-novo HF. Similarly, patients with beta-blockers had better survival 
in ADHF with a marginal significance. The effect of RAS inhibitors and MRA appeared to be 
neutral in both de-novo and ADHF patients (Figure S7 and Figure S8).  
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Figure S6 Outcomes according to onset of HF 
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Figure S7 Drug efficacy in de-novo HFiEF 
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Figure S8 Drug efficacy in acutely-decompensated HFiEF 
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Figure S9 Impact of digoxin and loop diuretics on 4-year mortality in HFiEF patients 
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Patients with and without follow-up echocardiography 
Table S7 Clinical characteristics of patients with HFrEF according to presence of 1 year follow 
up echocardiography 
N=2,319 
Without 
echocardiography 
(n=810) 
With 
echocardiography 
(n=1,509) 
p-value 
Demographic data    
Age (years) 67.9±13.9 62.4±15.2 <0.001 
Men (%) 477 (58.9) 937 (62.1) 0.131 
Body mass index (kg/m2)    
De novo heart failure (%) 430 (53.1) 833 (55.2) 0.329 
Past Medical History    
Hypertension 473 (58.4) 757 (50.2) <0.001 
Diabetes mellitus 310 (38.3) 495 (32.8) 0.008 
Ischemic Heart Disease 242 (29.9) 378 (25.1) 0.013 
Valvular Heart Disease 56 (6.9) 131 (8.7) 0.136 
COPD 85 (10.5) 127 (8.4) 0.098 
Cerebrovascular disease 92 (11.4) 170 (11.3) 0.947 
Atrial fibrillation 201 (24.8) 326 (21.6) 0.079 
NYHA functional class (%)   0.050 
II 109 (13.5) 240 (15.9)  
III 298 (36.8) 595 (39.4)  
IV 403 (49.8) 674 (44.7)  
Physical exam at discharge    
Systolic blood pressure (mmHg) 133.8±29.9 127.7±28.2 <0.001 
Diastolic blood pressure (mmHg) 81.9±18.9 80.1±18.8 0.031 
Heart rate (beats per min) 97.6±25.4 94.7±24.7 0.008 
Echocardiography at index 
admission 
   
Left atrial diameter (mm) 48.1±8.4 47.7±9.0 0.310 
Left ventricular end diastolic 
diameter (mm) 
61.3±8.7 62.3±9.1 0.009 
Left ventricular end systolic 
diameter (mm) 
51.4±9.2 53.0±9.9 <0.001 
E/e’ 22.0±10.3 21.8±11.1 0.666 
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Left ventricular ejection fraction 
(%) 
27.9±7.1 26.2±7.4 <0.001 
Medication at discharge    
Beta-blocker 444 (54.8) 906 (60.0) 0.015 
RAS-inhibitor 642 (79.3) 1186 (78.6) 0.709 
MRA 413 (51.0) 840 (55.7) 0.031 
COPD, chronic obstructive pulmonary disease; HFrEF, heart failure with reduced ejection 
fraction; MRA, Mineralocorticoid receptor antagonist; NYHA, New York Heart Association; 
RAS-inhibitor, renin-angiotensin-system inhibitor 
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